ReviewJournal of thoracic disease2024
Farnesoid X receptor (FXR) as a potential therapeutic target for lung diseases: a narrative review.
Review in Journal of thoracic disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Gut microbiota-immune-metabolic crosstalk in acute lung injury: integrating the gut-lung axis from mechanism to therapeutic targeting.Seminars in immunopathology · 2026Review
- Regulation of PD-1PD-L1 Immune Checkpoints by Gut Microbiota Metabolites and Their Clinical Translational Research: A Review.Immunity, inflammation and disease · 2026Review
- Ursodeoxycholic acid inhibits feline infectious peritonitis virus infection through activating JAK-STAT signaling pathway-induced type I interferon.Microbiology spectrum · 2026Article
- CYP8B1 suppressed by Ras/ERK leads to cholesterol accumulation and bile acids reduction and facilitates hepatic tumorigenesis.Cancer & metabolism · 2026Article
- Mechanisms by which complex carbohydrates influence immune imbalance in COPD via the gut-lung axis: from colonic fermentation to pulmonary immune responses.Frontiers in nutrition · 2026Review
- Pharmacological Activation of FXR Attenuates Renal Fibrosis and Pyroptosis-Associated Signaling in Aldosterone-Infused Mice.Journal of inflammation research · 2026Article
- Disruption of the gut bile acid-microbiota axis precedes severe bronchopulmonary dysplasia in preterm infants.Frontiers in microbiology · 2025Article
- From Gut to Lung: The Role of Bile Acids in Rheumatoid Arthritis-Associated Interstitial Lung Disease (RA-ILD).Journal of inflammation research · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objective: Farnesoid X receptor (FXR), which is encoded by the Methods: The PubMed and National Center for Biotechnology Information (NCBI) online databases were searched to retrieve relevant articles published from 2000 to 2024. Key Content and Findings: FXR was originally found to be expressed in BA-targeted organs, such as the liver and intestine. However, recent studies have shown that FXR is also expressed in "non-classical" BA-targeted organs, such as the lung and blood vessels. FXR is not only involved in the pathophysiology of a series of diseases of the gastrointestinal tract and liver, but is also involved in various lung diseases. Recent evidence suggests that FXR participates in the pathogenesis of lung diseases through multiple mechanisms. In addition, FXR may be a potential therapeutic target for some lung diseases. For example, FXR has been reported to promote the occurrence and development of non-small cell lung cancer (NSCLC) by inducing the expression of programmed death ligand 1 (PD-L1) and subsequently suppressing anti-tumor immunity in the tumor microenvironment. Conclusions: In this review, we summarized the current knowledge of the roles of FXR in different lung diseases. A better understanding of the roles and mechanisms of FXR in lung diseases will provide new perspectives for the treatment of lung diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.